Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments

References

• Veale D, Gledhill LJ, Christodoulou P, et al. Body dysmorphic disorder in different settings: a systematic review and estimated weighted prevalence. Body Image. 2016 Sep;18:168–186. PubMed PMID: 27498379.
   PubMed Web of Science ®Google Scholar
• Bjornsson AS, Didie ER, Grant JE, et al. Age at onset and clinical correlates in body dysmorphic disorder. Compr Psychiatry. 2013 Oct;54(7):893–903. . PubMed PMID: 23643073; PubMed Central PMCID: PMCPMC3779493.
   PubMed Web of Science ®Google Scholar
• Neziroglu F, Barile N. Environmental factors in body dysmorphic disorder. In: Phillips KA, editor. Body dysmorphic disorder: advances in research and clinical practice. New York, NY: Oxford University Press; 2017. p. 277–284.
   Google Scholar
• Neziroglu F, Khemlani-Patel S, Veale D. Social learning theory and cognitive behavioral models of body dysmorphic disorder. Body Image. 2008 Mar;5(1):28–38. . PubMed PMID: 18337196.
   PubMed Web of Science ®Google Scholar
• Grace SA, Labuschagne I, Kaplan RA, et al. The neurobiology of body dysmorphic disorder: a systematic review and theoretical model. Neurosci Biobehav Rev. 2017 Dec;83:83–96. PubMed PMID: 29017915. .
   PubMed Web of Science ®Google Scholar
• Feusner JD, Townsend J, Bystritsky A, et al. Visual information processing of faces in body dysmorphic disorder. Arch Gen Psychiatry. 2007 Dec;64(12):1417–1425. . PubMed PMID: 18056550.
   PubMed Web of Science ®Google Scholar
• Buchanan BG, Rossell SL, Maller JJ, et al. Brain connectivity in body dysmorphic disorder compared with controls: a diffusion tensor imaging study. Psychol Med. 2013 Dec;43(12):2513–2521. . PubMed PMID: 23473554.
   PubMed Web of Science ®Google Scholar
• Feusner JD, Arienzo D, Li W, et al. White matter microstructure in body dysmorphic disorder and its clinical correlates. Psychiatry Res. 2013 Feb 28;211(2):132–140. PubMed PMID: 23375265; PubMed Central PMCID: PMCPMC3570702.
   PubMed Web of Science ®Google Scholar
• Feusner JD, Townsend J, Bystritsky A, et al. Regional brain volumes and symptom severity in body dysmorphic disorder. Psychiatry Res. 2009 May 15;172(2):161–167. . PubMed PMID: 19328661; PubMed Central PMCID: PMCPMC2736954.
   PubMed Web of Science ®Google Scholar
• Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005332. DOI:10.1002/14651858.CD005332.pub2. PubMed PMID: 19160252.
   PubMed Web of Science ®Google Scholar
• Vulink NC, Planting RS, Figee M, et al. Reduced striatal dopamine D2/3 receptor availability in body dysmorphic disorder. Eur Neuropsychopharmacol. 2016 Feb;26(2):350–356. . PubMed PMID: 26711686.
   PubMed Web of Science ®Google Scholar
• Monzani B, Rijsdijk F, Iervolino AC, et al. Evidence for a genetic overlap between body dysmorphic concerns and obsessive-compulsive symptoms in an adult female community twin sample. Am J Med Genet B Neuropsychiatr Genet. 2012 Jun;159B(4):376–382. . PubMed PMID: 22434544.
   PubMed Web of Science ®Google Scholar
• Allen A, Hollander E. Body dysmorphic disorder. Psychiatr Clin North Am. 2000 Sep;23(3):617–628. PubMed PMID: 10986731.
   PubMed Web of Science ®Google Scholar
• Simmons RA, Phillips KA. Core clinical features of body dysmorphic disorder: appearance preoccupations, negative emotions, core beliefs, and repetitive and avoidance behaviors. In: Phillips KA, editor. Body dysmorphic disorder: advances in research and clinical practice. New York, NY: Oxford University Press; 2017. p. 61–80.
   Google Scholar
• Phillips KA, Menard W, Fay C, et al. Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics. 2005 Jul;46(4):317–325. . PubMed PMID: 16000674; PubMed Central PMCID: PMCPMC1351257.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Diaz SF. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997 Sep;185(9):570–577. PubMed PMID: 9307619.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Pinto A, Hart AS, et al. A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder. J Psychiatr Res. 2012 Oct;46(10):1293–1299. PubMed PMID: 22819678; PubMed Central PMCID: PMCPMC3432724.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Hart AS, Simpson HB, et al. Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5. CNS Spectr. 2014 Feb;19(1):10–20. . PubMed PMID: 23659348; PubMed Central PMCID: PMCPMC4948290.
   PubMed Web of Science ®Google Scholar
• Didie ER, Walters MM, Pinto A, et al. A comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder and body dysmorphic disorder. Ann Clin Psychiatry. 2007 Jul;19(3):181–186. PubMed PMID: 17729020.
   PubMedGoogle Scholar
• Hanes KR. Neuropsychological performance in body dysmorphic disorder. J Int Neuropsychol Soc. 1998 Mar;4(2):167–171. PubMed PMID: 9529826.
   PubMed Web of Science ®Google Scholar
• Tukel R, Tihan AK, Ozturk N. A comparison of comorbidity in body dysmorphic disorder and obsessive-compulsive disorder. Ann Clin Psychiatry. 2013 Aug;25(3):210–216. PubMed PMID: 23926576.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Siniscalchi JM, McElroy SL Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatr Q. 2004 Winter;75(4):309–320. PubMed PMID: 15563049; PubMed Central PMCID: PMCPMC1613755.
   PubMed Web of Science ®Google Scholar
• Toh WL, Castle DJ, Mountjoy RL, et al. Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: revisiting this issue in light of DSM-5. Compr Psychiatry. 2017 Aug;77:100–108. PubMed PMID: 28651226.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Pinto A, Menard W, et al. Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders. Depress Anxiety. 2007;24(6):399–409. . PubMed PMID: 17041935; PubMed Central PMCID: PMCPMC2092450.
   PubMed Web of Science ®Google Scholar
• Association AP. Diagnostic and statistical manual of mental disorders. Fifth. (DSM-5). 5 ed. Arlington, VA: American Psychiatric Association; 2013.
   Google Scholar
• De La Vega D, Giner L, Courtet P. Suicidality in subjects with anxiety or obsessive-compulsive and related disorders: recent advances. Curr Psychiatry Rep. 2018 Mar 28;20(4):26. 10.1007/s11920-018-0885-z. PubMed PMID: 29594718.
   PubMed Web of Science ®Google Scholar
• Ruffolo JS, Phillips KA, Menard W, et al. Comorbidity of body dysmorphic disorder and eating disorders: severity of psychopathology and body image disturbance. Int J Eat Disord. 2006 Jan;39(1):11–19. . PubMed PMID: 16254870.
   PubMed Web of Science ®Google Scholar
• Veale D, Anson M, Miles S, et al. Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. Psychother Psychosom. 2014;83(6):341–353. . PubMed PMID: 25323062.
   PubMed Web of Science ®Google Scholar
• Krebs G, Fernandez de la Cruz L, Monzani B, et al. Long-term outcomes of cognitive-behavioral therapy for adolescent body dysmorphic disorder. Behav Ther. 2017 Jul;48(4):462–473. PubMed PMID: 28577583.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Asmundson GJ, Beck AT. The science of cognitive therapy. Behav Ther. 2013 Jun;44(2):199–212. PubMed PMID: 23611069.
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Fernandez de la Cruz L, Isomura K, et al. A pilot randomized controlled trial of cognitive-behavioral therapy for adolescents with body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):895–904. PubMed PMID: 26506580.
   PubMed Web of Science ®Google Scholar
• Hadley SJ, Greenberg J, Hollander E. Diagnosis and treatment of body dysmorphic disorder in adolescents. Curr Psychiatry Rep. 2002 4;Apr(2):108–113. PubMed PMID: 11914171.
   Google Scholar
• Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002 Apr;59(4):381–388. PubMed PMID: 11926939.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008 Mar;5(1):13–27. . PubMed PMID: 18325859; PubMed Central PMCID: PMCPMC2705931.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003 Jun;64(6):715–720. PubMed PMID: 12823088.
   PubMed Web of Science ®Google Scholar
• Rossell SL, Harrison BJ, Castle D. Can understanding the neurobiology of body dysmorphic disorder (BDD) inform treatment? Australas Psychiatry. 2015 Aug;23(4):361–364. . PubMed PMID: 26129816.
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999 Nov;56(11):1033–1039. PubMed PMID: 10565503.
   PubMed Web of Science ®Google Scholar
• Phillips K. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21:177–179.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Hollander E, Rasmussen SA, et al. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997;33(1):17–22. PubMed PMID: 9133747.
   PubMed Web of Science ®Google Scholar
• Allen A, Hadley SJ, Kaplan A, et al. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008 Feb;13(2):138–144. PubMed PMID: 18227745.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 2009 Jan;24(1):26–28. . PubMed PMID: 19060721; PubMed Central PMCID: PMCPMC2677723.
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the veterans health administration data sets. Am J Psychiatry. 2007 Jul;164(7):1044–1049. PubMed PMID: 17606656.
   PubMed Web of Science ®Google Scholar
• Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683–1696. PubMed PMID: 17440145.
   PubMed Web of Science ®Google Scholar
• Uzun O, Ozdemir B. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig. 2010;30(10):707–710. . PubMed PMID: 20701402.
   PubMed Web of Science ®Google Scholar
• Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005 May;162(5):1022–1023. . PubMed PMID: 15863817; PubMed Central PMCID: PMCPMC1613796.
   PubMed Web of Science ®Google Scholar
• Diniz JB, Costa DL, Cassab RC, et al. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. J Psychopharmacol. 2014 Jun;28(6):603–611. PubMed PMID: 24288238.
   PubMed Web of Science ®Google Scholar
• Goulia P, Mantas C, Bassukas ID, et al. Treatment with risperidone and venlafaxine of a patient with double-coded diagnosis of body dysmorphic disorder and delusional disorder somatic type. Hippokratia. 2011 Jul;15(3):286–287. PubMed PMID: 22435040; PubMed Central PMCID: PMCPMC3306049.
   PubMed Web of Science ®Google Scholar
• Nakaaki S, Murata Y, Furukawa TA. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci. 2008 Jun;62(3):370. . PubMed PMID: 18588607.
   PubMed Web of Science ®Google Scholar
• Grant JE. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry. 2001 Apr;62(4):297–298. PubMed PMID: 11379848.
   PubMed Web of Science ®Google Scholar
• Kim D, Ryba NL, Kalabalik J, et al. Critical review of the use of second-generation antipsychotics in obsessive-compulsive and related disorders. Drugs R D. 2018 Sep;18(3):167–189. 10.1007/s40268-018-0246-8. PubMed PMID: 30171515; PubMed Central PMCID: PMCPMC6131117.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Hart AS, Menard W, et al. Psychometric evaluation of the brown assessment of beliefs scale in body dysmorphic disorder. J Nerv Ment Dis. 2013 Jul;201(7):640–643. . PubMed PMID: 23817164; PubMed Central PMCID: PMCPMC3725596.
   PubMed Web of Science ®Google Scholar
• Chicago Uo. Milk thistle in body dysmorphic disorder. 2016. [cited 2018 Jul 02]. Available from: https://ClinicalTrials.gov/show/NCT02843451
   Google Scholar
• Lu P, Mamiya T, Lu L, et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res. 2010 Mar 5;207(2):387–393. PubMed PMID: 19857526.
   PubMed Web of Science ®Google Scholar
• Sayyah M, Boostani H, Pakseresht S, et al. Comparison of silybum marianum (L.) gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):362–365. . PubMed PMID: 20035818.
   PubMed Web of Science ®Google Scholar
• Hospital M. An open label trial of memantine in the treatment of bulimia nervosa and body dysmorphic disorder. 2009. Available from: https://ClinicalTrials.gov/show/NCT01038128
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317–324. . PubMed PMID: 14734594.
   PubMed Web of Science ®Google Scholar
• Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009 Feb;29(1):51–55. . PubMed PMID: 19142108.
   PubMed Web of Science ®Google Scholar
• Peeters M, Maloteaux JM, Hermans E. Distinct effects of amantadine and memantine on dopaminergic transmission in the rat striatum. Neurosci Lett. 2003 Jun 12;343(3):205–209. PubMed PMID: 12770697.
   PubMed Web of Science ®Google Scholar
• Hospital MG. D-cycloserine augmentation of behavior therapy for individuals with body dysmorphic disorder. Bethesda (MD): National Library of Medicine (US); 2008. ClinicalTrials.gov [Internet].
   Google Scholar
• Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008 Jun 15;63(12):1118–1126. . PubMed PMID: 18313643.
   PubMed Web of Science ®Google Scholar
• Krystal JH. Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biol Psychiatry. 2007 Oct 15;62(8):833–834. . PubMed PMID: 17916459.
   PubMed Web of Science ®Google Scholar
• Sulkowski ML, Geller DA, Lewin AB, et al. The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. Curr Psychiatry Rev. 2014;10(4):317–324. PubMed PMID: 25383074; PubMed Central PMCID: PMCPMC4223803. .
   PubMedGoogle Scholar
• Hospital MG. Oxytocin administration in BDD and OCD. 2014. [cited 2018 Jul 02]. Available from: https://ClinicalTrials.gov/show/NCT02671266
   Google Scholar
• Vasudeva SB, Hollander E. Body dysmorphic disorder in patients with autism spectrum disorder: a reflection of increased local processing and self-focus. Am J Psychiatry. 2017 Apr 1;174(4):313–316. . PubMed PMID: 28366095.
   PubMed Web of Science ®Google Scholar
• Center MM, Food, Administration D. Fluoxetine in pediatric body dysmorphic disorder. 2004. [cited 2018 Jul 02]. Available from: https://ClinicalTrials.gov/show/NCT00245635
   Google Scholar
• Hospital B, Pharma U Effectiveness of levetiracetam in the treatment of body dysmorphic disorder. 2004. [cited 2018 Jul 02]. Available from: https://ClinicalTrials.gov/show/NCT00265109
   Google Scholar
• Phillips KA, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009 May;14(5):252–260. PubMed PMID: 19407724; PubMed Central PMCID: PMCPMC2941874.
   PubMed Web of Science ®Google Scholar
• Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep;65(9):1219–1222. PubMed PMID: 15367048.
   PubMed Web of Science ®Google Scholar
• Coles ME, Phillips KA, Menard W, et al. Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006;23(1):26–33. . PubMed PMID: 16278832; PubMed Central PMCID: PMCPMC1397710
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861–9866. PubMed PMID: 15210974; PubMed Central PMCID: PMCPMC470764.
   PubMed Web of Science ®Google Scholar
• Phillips KA, McElroy SL, Keck PE Jr., et al. et al. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30(2):179–186. PubMed PMID: 7831453.
   PubMedGoogle Scholar
• Kelly MM, Zhang J, Phillips KA. The prevalence of body dysmorphic disorder and its clinical correlates in a VA primary care behavioral health clinic. Psychiatry Res. 2015 Jul 30;228(1):162–165. . PubMed PMID: 25935375.
   PubMed Web of Science ®Google Scholar
• Naini FB, Gill DS. Orthognathic surgery: principles, planning and practice. Chichester, UK: Wiley; 2017.
   Google Scholar
• Phillips KA, Albertini RS, Siniscalchi JM, et al. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001 Sep;62(9):721–727. PubMed PMID: 11681769.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Keshaviah A, Dougherty DD, et al. Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am J Psychiatry. 2016 Sep 1;173(9):887–895. . PubMed PMID: 27056606; PubMed Central PMCID: PMCPMC5009005.
   PubMed Web of Science ®Google Scholar
• Massachusetts General H, National Institute of Mental H, Rhode Island H. Effectiveness of escitalopram in the treatment of body dysmorphic disorder 2013 [updated March]. [cited 2018 Jul 02]. Available from: https://ClinicalTrials.gov/show/NCT00149799
   Google Scholar
• Amminger GP, Berger M, Rice SM, et al. Novel biotherapies are needed in youth mental health. Australas Psychiatry. 2017 Apr;25(2):117–120. . PubMed PMID: 28375061.
   PubMed Web of Science ®Google Scholar
• Nardo M, Casarotto PC, Gomes FV, et al. Cannabidiol reverses the mCPP-induced increase in marble-burying behavior. Fundam Clin Pharmacol. 2014 Oct;28(5):544–550. . PubMed PMID: 24118015.
   PubMed Web of Science ®Google Scholar
• Cooper JJ, Grant J. Refractory OCD due to thalamic infarct with response to dronabinol. J Neuropsychiatry Clin Neurosci. 2017 Winter;29(1):77–78. PubMed PMID: 27539378. .
   PubMed Web of Science ®Google Scholar
• Lochner C, Fineberg NA, Zohar J, et al. Comorbidity in obsessive-compulsive disorder (OCD): a report from the international college of obsessive-compulsive spectrum disorders (ICOCS). Compr Psychiatry. 2014 Oct;55(7):1513–1519. PubMed PMID: 25011690.
   PubMed Web of Science ®Google Scholar
• Fineberg N, Pampaloni I, Pallanti S, et al. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(6):313–322. .
   PubMed Web of Science ®Google Scholar
• Robb AS, Andersson C, Bellocchio EE, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6–17 years old): resultsfrom a pooled analysis of 2 studies. Prim Care Companion CNS Disord. 2011;13(1). DOI:10.4088/PCC.10m01008gry PubMed PMID: 21731831; PubMed Central PMCID: PMCPMC3121213.
   PubMedGoogle Scholar
• Costa DLC, Diniz JB, Requena G, et al. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017 Jul;78(7):e766–e773. PubMed PMID: 28617566.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Mohammadi MR, Bahraini S, et al. Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial. Iran J Psychiatry. 2017 Apr;12(2):134–141. PubMed PMID: 28659986; PubMed Central PMCID: PMCPMC5483239.
   PubMedGoogle Scholar
• Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: implications for interventions and therapeutics. World J Biol Psychiatry. 2016 Apr;17(3):174–186. . PubMed PMID: 26469219.
   PubMed Web of Science ®Google Scholar